A new driving mutation in lung cancer called NTRK1 has been found by researchers from University of Colorado and Dana-Farber Cancer Institute. It joins the family of driving mutations like EGFR, ALK, ROS1, and RET. What’s particularly interesting for this mutation is that an exisiting drug appears to target it (in preclinical studies). Note the linked article does NOT say the mutation is specific to NSCLC.
I’m hopeful we’ll have an approved FDA treatment for this mutation more quickly than usual (though I’m not holding my breath).
NTRK1: a new oncogene and target in lung cancer